Results 91 to 100 of about 18,821 (231)

Critical Role of P2Y12 Receptor in Regulation of Th17 Differentiation and Experimental Autoimmune Encephalomyelitis Pathogenesis

, 2017
Adenosine 5'-diphosphate is a key endogenous cell-signaling molecule that can activate P2 purinergic receptor family members. ADP-P2Y signaling is reported to be associated with inflammation, but its function in T cell differentiation and autoimmune ...
Jinfeng Zhou, Cuixia Yang, Shuai Chen, Weiming Lai, Changsheng Du, Yuan Gao, Chaoyan Qin, Yingying Cai   +7 more
core   +1 more source

The potential for biased signalling in the P2Y receptor family of GPCRs

British Journal of Pharmacology, EarlyView.
The purinergic receptor family is primarily activated by nucleotides, and contains members of both the G protein coupled‐receptor (GPCR) superfamily (P1 and P2Y) and ligand‐gated ion channels (P2X). The P2Y receptors are widely expressed in the human body, and given the ubiquitous nature of nucleotides, purinergic signalling is involved with a plethora
Claudia M. Sisk, Simon Pitchford, Graham Ladds   +2 more
wiley   +1 more source

Stage‐Associated Microglial Subpopulations and Dynamics in Vascular Pathogenesis of Oxygen‐Induced Retinopathy

Cell Proliferation, EarlyView.
In the oxygen‐induced retinopathy (OIR) mouse model, two distinct microglial subpopulations play opposing roles: highly glycolytic microglia (HGM) promote neovascular formation via Pkm2, while Mrc1/CD206‐positive phagocytosis‐associated microglia (PAM) facilitate its regression.
Yuan Ma, Ziye Chen, Baoyi Liu, Wen Ding, Runping Duan, Kangjie Kong, Zhuojun Xu, Jizhu Li, Jiali Ru, Dianlei Guo, Xiaoyue Wei, Yaping Liu, Zhuangling Lin, Yang Meng, Yuan Liu, Lan Jiang, Zitong Chen, Rebiya Tuxun, Chinling Tsai, Chunqiao Liu, Tao Li   +20 more
wiley   +1 more source

Cangrelor — Expanding therapeutic options in patients with acute coronary syndrome

Cardiology Journal
Cangrelor is the only intravenous P2Y12 receptor antagonist. It is an adenosine triphosphate analog that selectively, directly, and reversibly binds to the platelet P2Y12 receptors exerting its antiaggregatory effect. Cangrelor is characterized by linear,
Jacek Kubica, Piotr Adamski, Sławomir Dobrzycki, Robert Gajda, Mariusz Gąsior, Marek Gierlotka, Miłosz Jaguszewski, Jacek Legutko, Maciej Lesiak, Eliano P. Navarese, Piotr Niezgoda, Małgorzata Ostrowska, Tomasz Pawłowski, Agnieszka Tycińska, Julia M. Umińska, Adam Witkowski, Robert Gil   +16 more
doaj   +1 more source

Aspirin-free antithrombotic management following coronary stenting. Myth or reality?

REC: Interventional Cardiology (English Ed.), 2019
The use of aspirin in combination with a P2Y12 receptor inhibitor, also known as dual antiplatelet therapy, is at the cornerstone of treatment for patients undergoing coronary stenting.
Davide Capodanno, Roxana Mehran, Dominick J. Angiolillo   +2 more
doaj   +1 more source

Underdiagnosed and Undertreated: Obesity and Its Cardiometabolic Burden in Swedish Clinical Practice—Insights From the AROS Database

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To quantify real‐world diagnosis and treatment of obesity in Sweden, describe cardiometabolic comorbidity burden across obesity classes, and compare long‐term cardiovascular outcomes with the general population. Materials and Methods This population‐based cohort study used the AROS (Analysis of Real‐world data of patients with Obesity in ...
Viveca Ritsinger, Magnus Sundbom, Jonatan Dereke, Åsa Ericsson, Thomas Cars, Maria K. Svensson, Anna Norhammar   +6 more
wiley   +1 more source

P2Y12-ADP receptor antagonists: Days of future and past

World Journal of Cardiology, 2016
Antiplatelet therapy is the cornerstone of the therapeutic arsenal in coronary artery disease. Thanks to a better understanding in physiology, pharmacology and pharmacogenomics huge progress were made in the field of platelet reactivity inhibition thus allowing the expansion of percutaneous coronary intervention.
Laine, Marc, Bonello, Laurent, Paganelli, Franck   +2 more
openaire   +3 more sources

Cardiovascular Outcomes in a SELECT‐Like Obesity Cohort: Real‐World Insights From the Swedish AROS Database

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background In the SELECT trial, semaglutide reduced major adverse cardiovascular outcomes (MACE) in individuals with overweight or obesity and established cardiovascular disease (CVD) but without diabetes. However, real‐world cardiovascular event rates in comparable populations remain uncharacterised.
Viveca Ritsinger, Josefine Fagerström, Håkan Nero, Thomas Cars, Maria K. Svensson, Anna Norhammar   +5 more
wiley   +1 more source

ALOX15 links lipid metabolism to receptor trafficking in platelet activation

The FEBS Journal, EarlyView.
This schematic summarizes known and newly identified mechanisms of thrombin‐mediated platelet activation. In addition to classical thrombin‐induced PAR4 signaling pathways, thrombin activates an ALOX15–HETE–PKCθ–NMT1 signaling cascade that promotes protein myristoylation, facilitates receptor trafficking, and enhances PAR4 surface expression on ...
Yosef Eshetie Amare, Sharad Saxena, Serena Zacchigna   +2 more
wiley   +1 more source

Pharmacogenomics of Oral P2Y12 Receptor Blockers

Journal of Pharmacogenomics & Pharmacoproteomics, 2013
Dual antiplatelet therapy of aspirin and a P2Y12 receptor antagonist is the cornerstone of therapy for patients. Thienopyridines (ticlopidine, clopidogrel and prasugrel) are prodrugs that need cytochrome–mediated conversion to active metabolites to block P2Y12 receptors and subsequent ADP-induced platelet aggregation.
openaire   +1 more source